202197-78-2 Usage
General Description
4-CHLORO-7-IODOQUINAZOLINE is a chemical compound with the molecular formula C8H5ClIN2. It is a heterocyclic compound that contains a quinazoline ring system with chlorine and iodine substituents attached to it. 4-CHLORO-7-IODOQUINAZOLINE has potential applications in the field of pharmaceuticals and agrochemicals due to its ability to act as a building block in the synthesis of various organic compounds. It may also have biological activity as a potential drug candidate or as a precursor to other biologically active molecules. Further research and studies are needed to fully understand the potential uses and properties of 4-CHLORO-7-IODOQUINAZOLINE.
Check Digit Verification of cas no
The CAS Registry Mumber 202197-78-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,1,9 and 7 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 202197-78:
(8*2)+(7*0)+(6*2)+(5*1)+(4*9)+(3*7)+(2*7)+(1*8)=112
112 % 10 = 2
So 202197-78-2 is a valid CAS Registry Number.
202197-78-2Relevant articles and documents
Novel quinazoline-containing compound, and intermediate and application thereof
-
, (2021/06/12)
The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
-
, (2015/12/18)
A pharmaceutical formulation comprising the compound of formula
Anilinoquinazaolines as protein tyrosine kianse inhibitors
-
Page/Page column 47, (2008/06/13)
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
